The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

Health Canada has approved an RSV vaccine for adults over the age of 60 — something many doctors were "happy" to learn. The agency approved GSK’s Arexvy vaccine for the prevention of RSV ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The Food and Drug Administration Wednesday approved Arexvy, the first vaccine against severe respiratory syncytial virus, more commonly known as RSV. Highly contagious, RSV causes infections of ...

The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.

Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. Arexvy had an exceptional launch and generated £1.2 billion in sales in 2023.

Well in advance of the fall and winter RSV season, GSK's vaccine Arexvy is now available in major U.S. retail pharmacies, the company said.